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Editorial
ECAM is waiting for eCAM
Edwin L. Cooper
Laboratory of Comparative Neuroimmunology, Department of Neurobiology, David Geffen School of Medicine
at UCLA, University of California, Los Angeles, CA 90095-1763, USA
To wait is to live. Every aspect of our existence requires,
demands and includes waiting. We wait for our research grants
to be funded, our manuscripts to be accepted. For those of us
who are on the way up, we wait to be promoted based on our
scholarly involvement. Some of us, in fact, most of us are pro-
fessors of various ranks and disciplines in universities through-
out the world. Regardless of rank, we must also wait for
responses (favorable we hope) fromour students (mostlymedi-
cal) who we anticipate will submit clear and objective polite
commentsconcerningmeritsofourteachingefforts.Weexpect
the same from referees of our manuscripts. Thus we all wait.
Waiting has permeated other areas, perhaps less tangible to
us as biomedical researchers. There is the well-known theatre
piece of Samuel Beckett: ‘Waiting for Godot’ which empha-
sizes a philosophical (existentialist) view of waiting connected
to our living. Closer to home, Azumi et al. (1) even use this
theme of ‘Waiting for Godot’ in a search for molecular link-
ages between the immune systems of invertebrate animals
(protochordates are our nearest ancestors) and vertebrates.
Thus, the pervasiveness of waiting always includes that which
may be uncertain and may be accompanied by either the thrill
and/or dread of waiting. Then moving closer to biomedical
research before the invertebrate and vertebrate connection,
‘Waiting for the End’ by Niels K. Jerne (2) prefaces the then
current state of immunology in advance of network theory
and then clonal selection that of course we know as a Darwin-
ian corollary. Both Beckett and Jerne, Nobel Laureates, poles
apart, focused on waiting from the point of view of two widely
different disciplines. There is even a hint of this theme in one
of the many serious essays of Janeway (3) in relation to
immunology and the asymptote,a line or curve that approaches
a given curve arbitrarily close. And even more recently we
recognize an extension of this direction. There is an attempt
to solidify years of grappling with invertebrate immune
systems and understanding signaling so essential for initiating
an immune response beginning with the perception and recep-
tion of an antigen, and its fit to a proper receptor (4,5).
Our entry into this debate of course refers to TOLL, one of
the prominent pathways that explain the intimacy of linkages
of early mechanisms of invertebrate innate immune systems
with those of vertebrates—leaving less of a schism than we
would have thought existed during the 19th century. This
was an incredibly unique period in biology when Metchnikoff
destroyed the prevailing monolith that shrouded immunology
but dividing us into the cellular and humoral camps (6). And
of course he accomplished this coup following enormous
persistence using evidence derived from the observation of
phagocytosis in marine invertebrates. Just think, simple
observations of innate responses in invertebrates changed the
very course of immunology and there is promise of inverte-
brates moving us into other directions of even more clinical
relevance (5,7).
Signaling in the organism especially in the immune system
through the TOLL pathway is indeed crucial to understanding
how the immune system works at the cellular level in humans.
Animal models have been one current subject upon which
eCAM has focused. Having just returned from active participa-
tion at the 13th EFIS (European Federation Immunological
Societies: Symposium on Signaling, Balaton, Hungary), I am
particularly eager to draw our reader’s attention to this subject
of signaling as it could relate to CAM (8,9). For this would
widen the boundaries of eCAM and increase its depth (10).
Why is ECAM waiting for eCAM? In our quest to raise the
standards of CAM we are searching for evidence. Now at the
completion of Volume 2, where are we? eCAM has covered
all aspects of research that require evidence from representa-
tives of every group in the animal kingdom (invertebrates
and vertebrates). And the material presented concerning
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following reasons. First, invertebrates have survived millions
of years partly due to their capacity to reproduce and to their
amazing capacity to synthesize and secrete protective mole-
cules, especially those species that are sessile and unable to
move and therefore dodge the attacks by territorial predators.
This includes the sponges, echinoderms and the protochor-
dates. However, all invertebrates do produce these molecules
and they all are not necessarily sessile. Second, we believe
that eCAM has so far been balanced in its publications that
seek a broad approach to the problem of creating an evidence
base. In my opinion, however, eCAM ever so young, still needs
to include more clinical papers and that is why CAM is waiting
for eCAM. This should come in due course since from our birth
we have been listed in PubMed and now retroactive to
Volume 1 an early listing in ISI, charting us on the road to
an impact factor.
How long will we wait and will the nature of submissions of
high quality require prolonged waiting? What is our formula
for eCAM so that we can diminish the time that we are waiting
for CAM and clinical relevance? First, we can look at what we
have published in an attempt to showcase eCAM as a journal
that publishes work of high quality and relevance to CAM.
Second, although the first point of my editorial emphasizes
waiting as inescapable, there should be another formula that
will lessen the time that CAM is waiting for eCAM. What
will lessen the waiting time for eCAM to deliver credible
CAM using the golden pyramid of Goldrosen and Strauss
(11) as it pertains to increasing the quality of CAM pub-
lications? Although emphasizing immunology, the formula is
applicable to any discipline or disease as long as biomedical
researchers have the patience and resources to delve deeper
and to become rigorous in their analyses.
At the heart of evidence are ideas. In the first part of his lec-
ture series in eCAM, Alex Hankey (12) stresses the importance
of the role of the development of theory in the advancement of
evidence-based CAM, proposing that CAM modalities can
stimulate new approaches to biological regulation that, if suc-
cessfully developed, could result in a major paradigm shift in
both biology and medicine, which will benefit all interested
parties: consumers, health professionals, scientists, institutions
and governments. And in our third issue of the year, Carlo
Ventura (10), urging us to see CAM in a new light, writes of
the subtle entanglement among different CAM systems,
suggesting that CAM modalities may deeply affect both the
signaling and transcriptional level of cellular homeostasis.
He closes with the proposal that functional genomics and pro-
teomics and the comprehension of the cell signaling networks
may substantially contribute to the development of a molecular
evidence-based CAM. Jose Olalde Rangel’s (13) lecture series
takes us step by step through the systemic theory from an
explanation of the existence of disease to clinical evidence of
its efficacy. He proposes that modern biophysics may provide
the long sought explanation that bridges the abyss between the
East and West as is illustrated symbolically on the cover of
eCAM by the woodblock print of Hiroshige.
In our search for inclusion of clinical papers, we understand
that the great economic resources required to reach the top of
the aforementioned golden pyramid are not always available.
With lack of funding, again clinicians and scientists are forced
to wait. In this case, the waiting period could be a time to
develop hypotheses to explain the results that have been
achieved in individuals and trials conducted lower on the
golden pyramid. This is due to the lack of resources for
randomized control trials or for myriad other reasons that
abound in CAM such as the lack of an appropriate placebo.
Some of the greatest discoveries of science have occurred
when a scientific mind has wandered out of the daily clinical
world or laboratory and into nature, where similar phenomena
may be found that lead to radical discovery. A classic example
of this is Michael Zasloff’s discovery of magainins and other
antimicrobial agents of animal origin (14). Hypotheses could
connect clinicians with basic scientists and lead to the forma-
tion of a carefully laid evidence base. The ideas that come in
the waiting will create bridges between previously uncon-
nected fields of CAM, as well as between basic and clinical
science, when working together (with funding) could quickly
make the golden pyramid a reality.
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